Comparison of Treatments for Localized Prostate Cancer

Categories: Winter 2025

small tiger in snow This study examined different treatments for localized prostate cancer and their effect on long-term survival. Localized prostate cancer means the cancer has not spread beyond the prostate. There is still debate overwhich treatment is most effective. The researchers used data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry, which included over 11,000 men from community-based medical centers. All participants had prostate cancer that had been confirmed by biopsy and had not spread beyond the prostate. They were followed for a median of 9.4 years, with some being followed for over 13 years. The study included men with a range of cancer risks, from low to high, and all had at least one year of follow-up data.

The men in the study received one of five main types of treatment: radical prostatectomy (surgery to remove the prostate), brachytherapy (a type of internal radiation seed implantation), external beam radiation therapy, hormone therapy (called primary androgen deprivation therapy or PADT), or were simply monitored through active surveillance or watchful waiting. After adjusting for factors like age and cancer severity using a tool called the CAPRA score, the researchers compared the risk of dying from prostate cancer for each treatment group. They found that, overall, men who had surgery had the lowest risk of prostate cancer death. Men who received radiation or hormone therapy, or who were monitored without active treatment, had higher risks of dying from their cancer. Specifically, the risk of dying from prostate cancer was about 50–60% higher for men who received radiation compared to surgery, and more than double for those who had hormone therapy. However, the differences in survival were much smaller for men with low-risk prostate cancer. For these men, monitoring or other non-surgical options might be appropriate.

The study had several significant limitations. Since this was not a randomized trial, patients and doctors chose the treatment based on personal preferences and medical history, which could affect the results. Also, prostate cancer treatments have improved over the years, so some of the results may not fully reflect current options.

In conclusion, this large study suggests that surgery may offer better long-term survival for men with higher- risk localized prostate small Eiffel Tower cancer. For men with low-risk cancer, the differences between treatments were not as significant. These findings support the concept that treatment should be based on each patient’s risk level and personal health factors. Still, more evidence from long-term clinical trials is needed to confirm the optimal approach for different patient types.